Genome dark matter provides clues to fighting prostate cancer

Through studying the dark matter of the human genome, a team from the University of Michigan has shed light on how the hormone androgen drives prostate cancer and suggested a potential target for future therapy.

Credit: Shutterstock / Black Prometheus

Senior author Arul Chinnaiyan and colleagues have identified a gene they have called ARLNC1 that controls signals from the androgen receptor, which plays as key role in prostate cancer.

As reported in Nature Genetics, reducing the expression of this long non-coding RNA (lncRNA) in mice resulted in cancer cell death, thereby pointing to a potential target for therapy.

Currently, treatments aim to block the androgen receptor to prevent tumor growth, but the majority of patients become resistant to these therapies and go on to develop a challenging form of the disease called metastatic castration-resistant prostate cancer.

"The androgen receptor is an important target in prostate cancer. Understanding that target is important. This study identifies a feedback loop that we could potentially disrupt as an alternative to blocking the androgen receptor directly," explains Chinnaiyan.

lncRNAs are described as the dark matter of the genome because researchers know so little about them. While searching for lncRNAs that may contribute to prostate cancer, Chinnaiyan and colleagues found that ARLNC1 is increased in prostate cancer, compared with in benign prostate tissue.

The gene was also associated with androgen receptor signaling. The team reports that the androgen receptor induces the expression of ARLNC1, which then binds to the androgen receptor messenger RNA transcript. This stabilizes the level of androgen receptor, which then feeds back to sustain ARLNC1.

“You're creating or stabilizing more androgen receptor signaling in general and driving this oncogenic pathway forward,” says Chinnaiyan. “We're envisioning a potential therapy against ARLNC1 in combination with therapy to block the androgen receptor - which would hit the target and also this positive feedback loop.”

Blocking ARLNC1 in cell lines that expressed the androgen receptor caused cancer cell death and prevented tumor growth. In mice, increasing ARLNC1 expression resulted in the growth of large tumors, while reducing its expression caused tumors to shrink.

Chinnaiyan says the team want to continue characterizing the dark matter of the genome since there are a number of lncRNAs that they do not understand the function of.

“Some of them will certainly be very useful as cancer biomarkers and we think a subset are important in biological processes," he concludes.

Sally Robertson

Written by

Sally Robertson

Sally has a Bachelor's Degree in Biomedical Sciences (B.Sc.). She is a specialist in reviewing and summarising the latest findings across all areas of medicine covered in major, high-impact, world-leading international medical journals, international press conferences and bulletins from governmental agencies and regulatory bodies. At News-Medical, Sally generates daily news features, life science articles and interview coverage.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2019, June 19). Genome dark matter provides clues to fighting prostate cancer. News-Medical. Retrieved on July 16, 2019 from

  • MLA

    Robertson, Sally. "Genome dark matter provides clues to fighting prostate cancer". News-Medical. 16 July 2019. <>.

  • Chicago

    Robertson, Sally. "Genome dark matter provides clues to fighting prostate cancer". News-Medical. (accessed July 16, 2019).

  • Harvard

    Robertson, Sally. 2019. Genome dark matter provides clues to fighting prostate cancer. News-Medical, viewed 16 July 2019,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
How cell-free DNA can be targeted to prevent spread of tumors